PURPOSE: To establish the age- and sex-specific prevalence of open-angle glaucoma (OAG) subsuming pseudoexfoliation (PEX) in the city of Reykjavik. METHODS: Participants 50 years of age and older who were part of the Reykjavik Eye Study and classified as having glaucoma were divided into three categories:Category 1: two or more of the following based on optic nerve stereophotograph reading: vertical cup to disc ratio (VCDR) 97.5th percentile (>0.7), focal glaucomatous disc change, C/D asymmetry of 97.5th percentile difference between eyes (>0.2) as well as glaucomatous visual field defect (GVFD). Category 2: 99.5th percentile of VCDR (>0.8) and 99.5% percentile difference between eyes (>/=0.3), without a GVFD. Category 3: VA<3/60 and IOP>99.5th percentile or VA <3/60 and evidence of filtering surgery. For a glaucoma suspect, one of the following was present: VCDR>99.5th percentile (>0.8), focal glaucomatous disc change, C/D asymmetry of 99.5th percentile (> or =0.3), GVFD only, IOP> or =23 mmHg (97.5 percentile). PEX was diagnosed by the presence of a central shield and/or a peripheral band on the anterior lens capsule. RESULTS: Of 42 persons (22 males and 20 females) with OAG, 13 (31.0%) had PEX. The minimum prevalence of OAG was 4.0% (42/1045) (95% CI 2.8-5.2) for those 50 years and older and 10.3% (95% CI 8.5-12.2) for PEX. The prevalence of OAG increases with age (OR=1.10/year, 95% CI 1.07-1.13, P=0.000) and the same applies for the prevalence of PEX, OR=1.10 (95% CI 1.07-1.12, P=0.000). CONCLUSION: There is a 10% annual increase for both OAG and PEX in persons 50 years and older.
PURPOSE: To establish the age- and sex-specific prevalence of open-angle glaucoma (OAG) subsuming pseudoexfoliation (PEX) in the city of Reykjavik. METHODS:Participants 50 years of age and older who were part of the Reykjavik Eye Study and classified as having glaucoma were divided into three categories:Category 1: two or more of the following based on optic nerve stereophotograph reading: vertical cup to disc ratio (VCDR) 97.5th percentile (>0.7), focal glaucomatous disc change, C/D asymmetry of 97.5th percentile difference between eyes (>0.2) as well as glaucomatous visual field defect (GVFD). Category 2: 99.5th percentile of VCDR (>0.8) and 99.5% percentile difference between eyes (>/=0.3), without a GVFD. Category 3: VA<3/60 and IOP>99.5th percentile or VA <3/60 and evidence of filtering surgery. For a glaucoma suspect, one of the following was present: VCDR>99.5th percentile (>0.8), focal glaucomatous disc change, C/D asymmetry of 99.5th percentile (> or =0.3), GVFD only, IOP> or =23 mmHg (97.5 percentile). PEX was diagnosed by the presence of a central shield and/or a peripheral band on the anterior lens capsule. RESULTS: Of 42 persons (22 males and 20 females) with OAG, 13 (31.0%) had PEX. The minimum prevalence of OAG was 4.0% (42/1045) (95% CI 2.8-5.2) for those 50 years and older and 10.3% (95% CI 8.5-12.2) for PEX. The prevalence of OAG increases with age (OR=1.10/year, 95% CI 1.07-1.13, P=0.000) and the same applies for the prevalence of PEX, OR=1.10 (95% CI 1.07-1.12, P=0.000). CONCLUSION: There is a 10% annual increase for both OAG and PEX in persons 50 years and older.
Authors: Gudmar Thorleifsson; G Bragi Walters; Alex W Hewitt; Gisli Masson; Agnar Helgason; Andrew DeWan; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Sigurjon A Gudjonsson; Kristinn P Magnusson; Hreinn Stefansson; Dennis S C Lam; Pancy O S Tam; Gudrun J Gudmundsdottir; Laura Southgate; Kathryn P Burdon; Maria Soffia Gottfredsdottir; Micheala A Aldred; Paul Mitchell; David St Clair; David A Collier; Nelson Tang; Orn Sveinsson; Stuart Macgregor; Nicholas G Martin; Angela J Cree; Jane Gibson; Alex Macleod; Aby Jacob; Sarah Ennis; Terri L Young; Juliana C N Chan; Wojciech S S Karwatowski; Christopher J Hammond; Kristjan Thordarson; Mingzhi Zhang; Claes Wadelius; Andrew J Lotery; Richard C Trembath; Chi Pui Pang; Josephine Hoh; Jamie E Craig; Augustine Kong; David A Mackey; Fridbert Jonasson; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2010-09-12 Impact factor: 38.330
Authors: K F Damji; A G P Konstas; J M Liebmann; W G Hodge; N G Ziakas; S Giannikakis; G Mintsioulis; A Merkur; Y Pan; R Ritch Journal: Br J Ophthalmol Date: 2006-05-03 Impact factor: 4.638
Authors: Tanya T Khan; Guorong Li; Iris D Navarro; Rama D Kastury; Carol J Zeil; Taras M Semchyshyn; Frank J Moya; David L Epstein; Pedro Gonzalez; Pratap Challa Journal: Mol Vis Date: 2010-11-02 Impact factor: 2.367